"I am delighted to promote these two experienced professionals to our senior management team", said Dr. Aiping Young, Lorus' President and CEO. "Their skills and knowledge will allow us to progress our novel anticancer drugs towards commercialization and seize emerging opportunities to accelerate the growth of our business."
Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.
This press release contains forward-looking statements within the
meaning of Canadian and U.S. securities laws. Such statements include, but
are not limited to, statements relating to: financings and corporate
reorganizations, the establishment of corporate alliances, the Company's
plans, objectives, expectations and intentions and other statements
including words such as "continue", "expect", "intend", "will", "should",
"would", "may", and other similar expressions. Such statements reflect our
current views with respect to future events an
|SOURCE Lorus Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved